[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Halil Ata BIÇAKÇIOĞLU\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100654907","alb-prf-as-an-adjunct-to-regenerative-periodontal-surgery-100654907",false,"NCT07805317","Alb-PRF as an Adjunct to Regenerative Periodontal Surgery","Clinical and Radiographic Effects of Albumin Platelet-Rich Fibrin as an Adjunct to Regenerative Periodontal Surgery: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosis of Stage III periodontitis according to the 2017 classification of periodontal and peri-implant diseases and conditions.\n* Completion of nonsurgical periodontal therapy and oral hygiene instruction before surgical treatment.\n* Presence of at least one interproximal intrabony periodontal defect considered suitable for regenerative periodontal surgery.\n* Residual probing depth of at least 6 mm and clinical attachment loss of at least 6 mm at the selected site following nonsurgical periodontal therapy.\n* Radiographic evidence of an intrabony defect component of at least 3 mm at the selected site.\n* Adequate plaque control and compliance with oral hygiene instructions.\n* Ability to understand the study procedures, provide written informed consent, and attend all scheduled follow-up visits.\n\nExclusion Criteria:\n\n* Current smoking or smoking cessation within the previous 6 months.\n* Uncontrolled diabetes mellitus, serious cardiovascular disease, autoimmune disease, liver or kidney failure, immunodeficiency, or another systemic condition that may adversely affect periodontal healing or surgical treatment.\n* Pregnancy or lactation.\n* Presence of a hematologic disorder, bleeding disorder, anticoagulant therapy, or another condition that may interfere with venous blood collection or periodontal surgery.\n* Use of antibiotics, systemic corticosteroids, immunosuppressive agents, bisphosphonates, antiresorptive agents, or other medications known to affect periodontal or bone healing within the previous 6 months.\n* Periodontal surgical treatment at the selected site within the previous 6 months.\n* Acute periodontal or endodontic infection at the selected site.\n* Untreated endodontic lesions, root fractures, extensive caries, or a hopeless prognosis involving the selected tooth.\n* Class II or III furcation involvement associated with the selected defect.\n* Known hypersensitivity to any material used in the study.\n* Inadequate oral hygiene or inability to meet the plaque-control requirements of the study protocol.\n* Current orthodontic treatment.\n* Inability or unwillingness to attend the scheduled follow-up visits.","ALL","18 Years","65 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","Periodontitis is characterized by the progressive destruction of tooth-supporting tissues and may lead to the formation of intrabony periodontal defects. Regenerative periodontal surgery aims to promote the reconstruction of the periodontal attachment apparatus and reduce residual defect dimensions. Albumin platelet-rich fibrin (Alb-PRF) is an autologous blood-derived biomaterial that combines an albumin-based matrix with platelet-rich fibrin components.\n\nThis randomized controlled clinical trial will evaluate the clinical and radiographic effects of Alb-PRF as an adjunct to regenerative periodontal surgery in patients with periodontitis-associated intrabony defects. Twenty-four participants will be randomly allocated to two parallel treatment groups. Both groups will undergo regenerative periodontal surgery involving defect debridement, root surface conditioning with EDTA, and placement of an allogeneic bone graft. In the experimental group, Alb-PRF will additionally be applied to the intrabony defect.\n\nThe primary outcome will be clinical attachment level gain at 6 months. Secondary outcomes will include probing depth, radiographic defect fill, early wound healing, postoperative pain, oral health-related quality of life, and adverse events. Participants will be followed for 9 months.",[27,28,29],"Periodontitis","Periodontitis Stage III","Periodontal Intrabony Defects",[31,32,33,34,35,36,37,38,39],"Albumin Platelet-Rich Fibrin","Alb-PRF","Regenerative Periodontal Surgery","Periodontal Intrabony Defect","Periodontal Regeneration","Allogeneic Bone Graft","EDTA Root Surface Conditioning","Clinical Attachment Level","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-09-01",{"date":43,"type":44},"2026-09-04","ACTUAL",{"date":46,"type":21},"2027-01-01",{"date":48,"type":21},"2028-09-01",{"name":50,"class":51},"Halil Ata BIÇAKÇIOĞLU","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":5},"100654108","alb-prf-as-an-adjunct-to-nonsurgical-periodontal-therapy-100654108","NCT07794046","Alb-PRF as an Adjunct to Nonsurgical Periodontal Therapy","Clinical and Microbiological Effects of Intrapocket Albumin Platelet-Rich Fibrin as an Adjunct to Nonsurgical Periodontal Therapy: A Randomized Split-Mouth Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 to 65 years.\n* Diagnosis of periodontitis according to the 2017 classification of periodontal and peri-implant diseases and conditions.\n* Presence of at least two clinically comparable periodontal sites within the same mouth that are suitable for a split-mouth design.\n* Periodontal probing depth of 5 mm or greater at the sites selected for randomization.\n* No systemic condition that would contraindicate nonsurgical periodontal therapy or adversely affect periodontal healing.\n* No current use of medications known to affect periodontal tissue healing.\n* No periodontal surgical treatment within the previous 6 months.\n* Ability to understand the study procedures, provide written informed consent, and attend the scheduled follow-up visits.\n\nExclusion Criteria:\n\n* Current smoking or smoking cessation within the previous 6 months.\n* Diabetes mellitus, uncontrolled hypertension, serious cardiovascular disease, autoimmune disease, liver failure, kidney failure, or another systemic condition that may adversely affect periodontal healing or treatment.\n* Use of antibiotics, corticosteroids, bisphosphonates, antiresorptive agents, immunosuppressive agents, or other medications known to affect periodontal healing within the previous 6 months.\n* Pregnancy or lactation.\n* Acute periodontal abscess or acute endodontic infection at a selected study site.\n* Hematologic disease, bleeding disorder, anticoagulant therapy, or another condition that may interfere with venous blood collection.\n* Known hypersensitivity to any material used in the study.\n* Inadequate oral hygiene or inability to meet the oral hygiene requirements of the study protocol.\n* Current orthodontic treatment.\n* Inability or unwillingness to attend the scheduled follow-up visits.",{"count":20,"type":21},[24],"Periodontitis is an inflammatory disease that damages the tissues supporting the teeth. Nonsurgical periodontal therapy is the standard initial treatment, but deep periodontal pockets may remain after treatment. Albumin platelet-rich fibrin (Alb-PRF) is an autologous material prepared from the participant's own blood and applied locally to support periodontal healing.\n\nThe main purpose of this study is to determine whether applying Alb-PRF into periodontal pockets in addition to nonsurgical periodontal therapy provides greater clinical improvement than nonsurgical periodontal therapy alone. The study will also evaluate whether the additional application of Alb-PRF affects the levels of selected bacteria associated with periodontitis.\n\nThis randomized split-mouth study will include 24 adults with periodontitis. In each participant, matched periodontal sites will be randomly assigned to receive either nonsurgical periodontal therapy alone or nonsurgical periodontal therapy followed by an intrapocket application of Alb-PRF. Clinical periodontal measurements will be recorded at baseline and at 1, 3, and 6 months. Subgingival plaque samples will be collected from the same sites at baseline and 30 days after treatment. The primary outcome is the reduction in periodontal probing depth from baseline to 3 months.",[27],[31,32,64,65,66,67,68,69,70,71,72,73,74],"Nonsurgical Periodontal Therapy","Scaling and Root Planing","Intrapocket Application","Periodontal Pocket","Autologous Platelet Concentrate","Split-Mouth Clinical Trial","Subgingival Microbiota","Quantitative Real-Time PCR","Porphyromonas gingivalis","Aggregatibacter actinomycetemcomitans","Prevotella intermedia","2026-08-26",{"date":77,"type":44},"2026-08-31",{"date":79,"type":21},"2026-12-01",{"date":81,"type":21},"2027-12-01",{"name":50,"class":51},""]